SOX2 and neoplasm: Both fludarabine and ruxolitinib treatments exhibit significant impact on the tumour growth of 22Rv1 line (Figure S6F,G), and diminish the protein level of STAT1, BMI1, SOX2 and NANOG in 22Rv1 tumours when compared with vehicle control (Figure S6H).